Swedish Orphan Biovitrum and Dongbao in cross-licensing deal to market each other's products in China and Europe

8 July 2010

Stockholm-based Swedish Orphan Biovitrum (SOB) and Chinese firm Dongbao intend to form a strategic commercial alliance, whereby the former would be the marketing and sales partner of choice for Dongbao's pipeline of biopharmaceuticals and other drugs in Europe and the latter would be the reciprocal partner for SOB's marketed and pipeline products in China.

The alliance would be a partnership where both parties will benefit in two ways. First, each party secures a marketing and sales partner for its own products in an important new territory, China in the case of SOB and Europe in the case of Dongbao. Second, each party gains access to a new portfolio of products for its home markets.

The companies also announced that they intend to complete the first stage of the commercial alliance by completing ongoing negotiations regarding the following products:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK